CRTC2 as a novel prognostic biomarker for worse pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with prostate cancer.
Hakmin LeeMinseung LeeSung Kyu HongPublished in: Investigative and clinical urology (2019)
We found that high pGS patients showed significant differences in expression of several metabolism-related genes compared with low pGS patients. Among those genes, CRTC2 showed the strongest association with pathologic outcome, as well as postoperative survival.
Keyphrases
- prostate cancer
- radical prostatectomy
- end stage renal disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- type diabetes
- poor prognosis
- patients undergoing
- gene expression
- skeletal muscle
- transcription factor
- genome wide
- weight loss
- locally advanced
- adipose tissue
- genome wide analysis